|
| Press Releases |
|
 |
|
| Wednesday, May 28, 2025 |
|
|
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China |
| Eisai Co., Ltd. announced today that the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) has been approved in China for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. more info >> |
|
| Wednesday, May 21, 2025 |
|
|
Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025 |
| Eisai Co., Ltd. announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO25), which is taking place in Chicago, Illinois, and virtually,from May 30 to June 3. more info >> |
|
|
エーザイ、米国臨床腫瘍学会年次総会におけるがん領域の製品・開発品に関する発表 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、2025 年 5 月 30 日から6 月３日まで米国イリノイ州シカゴおよびバーチャル形式で開催される「米国臨床腫瘍学会（American Society of Clinical Oncology：ASCO）年次総会」（2025 ASCO Annual Meeting）において、当社のがん領域における製品・開発品の様々ながん種における最新知見を発表することをお知らせします。 more info >> |
|
| Friday, May 16, 2025 |
|
|
Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro |
| Eisai Co., Ltd. announced today that it has received notification from Japan's Ministry of Health, Labour, and Welfare (MHLW) that the "all-case surveillance" post-marketing observational study condition required at the time of approval of anticancer agent "Remitoro for Intravenous Drip Infusion 300microgram" (Denileukin Diftitox (Genetical Recombination)) for the indications of T-cell Lymphoma has been cleared. more info >> |
|
| Wednesday, April 30, 2025 |
|
|
Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star |
| Eisai Co., Ltd. announced today that its Representative Corporate Officer and CEO Haruo Naito has been selected to receive the Order of the Rising Sun, Gold and Silver Star at the 2025 Spring Conferment of Decorations. more info >> |
|
| Friday, April 18, 2025 |
|
|
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union |
| Eisai Co., Ltd. and Biogen Inc. announced today that the European Commission (EC) has granted the amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) Marketing Authorization (MA) in the European Union (EU). more info >> |
|
| Wednesday, April 16, 2025 |
|
|
エーザイとバイオジェン、「レケンビ」（レカネマブ）が欧州連合（EU）において早期アルツハイマー病の進行を抑制する初めての治療剤として承認を取得 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫、以下 エーザイ）とバイオジェン・インク（Nasdaq：BIIB、本社：米国マサチューセッツ州ケンブリッジ、CEO：Christopher A.Viehbacher、以下 バイオジェン）は、このたび、抗アミロイドベータ（Aβ）モノクローナル抗体「レケンビ®」（一般名：レカネマブ）について、欧州委員会（European Commission）より、欧州連合（EU）における販売承認を取得したことをお知らせします。 more info >> |
|
| Tuesday, April 1, 2025 |
|
|
Eisai to Divest Rights for Pariet in China to Peak Pharma |
| Eisai Co., Ltd. announced today that it has entered into an agreement to divest the rights for proton pump inhibitor Pariet (generic name: rabeprazole sodium) in China to Beijing Peak Biology Pharmaceuticals Co., Ltd., a CBC Group-controlled company. more info >> |
|
| Thursday, March 27, 2025 |
|
|
エーザイ、アルツハイマー・パーキンソン病学会において、レカネマブの長期実臨床データやバイオマーカーをはじめとするアルツハイマー病の最新成果を発表 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、抗 Aβプロトフィブリル＊抗体レカネマブ（一般名、製品名「レケンビ®」、米国ブランド名「LEQEMBI」）をはじめとする当社のアルツハイマー病（AD）ポートフォリオに関する最新研究成果について、口頭発表６演題を含む合計 16 演題を、4 月 1 日から 5 日までオーストリア・ウィーンおよびバーチャルで開催される「アルツハイマー・パーキンソン病学会において発表することをお知らせします。 more info >> |
|
| Tuesday, March 25, 2025 |
|
|
World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Award at the 12th Technology Management and Innovation Awards |
| Eisai Co., Ltd. announced today that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI" (lecanemab) for the treatment of early Alzheimer's disease (early AD ) has received the Prime Minister's Award at the 12th Technology Management and Innovation Awards hosted by the Japan Techno-Economics Society (JATES). more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
International Land Alliance Unveils New Revenue Model Featuring 100 Rental Homes in Cabo Oasis
Jul 18, 2025 21:00 HKT/SGT
|
|
|
Virturo Broker Launches Enhanced AI-Powered Trading Suite at London Investor Summit
Jul 18, 2025 19:00: JST
|
|
|
Virturo Broker Launches Enhanced AI-Powered Trading Suite at London Investor Summit
Jul 18, 2025 17:00 HKT/SGT
|
|
|
AI+穩定幣：第四範式推出穩定幣智能風控&智能合規解決方案
Jul 18, 2025 15:00 HKT/SGT
|
|
|
Doubleview Gold Corp Provides Comprehensive Update on Its Flagship Project - the Polymetallic Hat Deposit
Jul 18, 2025 14:09 HKT/SGT
|
|
|
康哲药业携手新交所 共话新兴市场产业国际化与医药出海新范式探索
Jul 18, 2025 13:00 HKT/SGT
|
|
|
歐洲協同作戰飛機（CCA）建立新的跨大西洋夥伴關係
Jul 18, 2025 11:00 HKT/SGT
|
|
|
Honda Koraidon First Showrun during Suzuka 8 Hours
Jul 18, 2025 11:06 JST
|
|
|
SJC2 optical submarine cable in operation
Jul 18, 2025 9:36 JST
|
|
|
Latest GA Autonomous Jet Demo Features Live Air-to-Air Engagement Capability
Jul 18, 2025 00:05 HKT/SGT
|
|
|
Belgian Aircrew Completes MQ-9B Training
Jul 18, 2025 00:05 HKT/SGT
|
|
|
A New Transatlantic Partnership for European CCA
Jul 18, 2025 00:00 HKT/SGT
|
|
|
IP Roundtable and International Publishing Forum held at Hong Kong Book Fair today
Jul 17, 2025 20:32 HKT/SGT
|
|
|
Cornerstone Robotics Signs MOU with NHG Health and NTU Singapore to Facilitate Accessibility of RAS to Patients in Singapore
Jul 17, 2025 18:45 HKT/SGT
|
|
|
MHI-AP Awarded Long-term Service Contract for the Garabogazkarbamid Fertilizer Plant in Turkmenistan
Jul 17, 2025 19:07 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
